Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

A roadmap for biomarker qualification

A collaborative effort between pharmaceutical companies, regulatory agencies and academia to qualify biomarkers for kidney toxicity provides a model for investigating and identifying reliable safety markers for preclinical applications.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Receiver operating characteristics (ROC) curve analysis.

References

  1. Dieterle, F. et al. Nat Biotechnol. 28, 463–469 (2010).

    Article  CAS  Google Scholar 

  2. Yu, Y. et al. Nat. Biotechnol. 28, 470–477 (2010).

    Article  CAS  Google Scholar 

  3. Vaidya, V.S. et al. Nat. Biotechnol. 28, 478–485 (2010).

    Article  CAS  Google Scholar 

  4. Ozer, J.S. et al. Nat. Biotechnol. 28, 486–494 (2010).

    Article  CAS  Google Scholar 

  5. Sistare, F.D. et al. Nat. Biotechnol. 28, 446–454 (2010).

    Article  CAS  Google Scholar 

  6. Dieterle, F. et al. Nat. Biotechnol. 28, 455–462 (2010).

    Article  CAS  Google Scholar 

  7. http://www.fda.gov/oc/initiatives/criticalpath/projectsummary/consortium.html

  8. http://www.fda.gov/oc/initiatives/criticalpath/

  9. Bonventre, J.V. et al. Nat. Biotechnol. 28, 436–440 (2010).

    Article  CAS  Google Scholar 

  10. Hanley, J.A. & NcNeil, B.J. Radiology 143, 29–36 (1982).

    Article  CAS  Google Scholar 

  11. The Food and Drug Administration Biomarker Qualification Review Team. Review of Qualification Data for Biomarkers of Nephrotoxicity Submitted by the Predictive Safety Testing Consortium (FDA CDER, 21 February 2008).

  12. EMEA. Biomarkers Qualification: Guidance to Applicants (doc. ref. EMEA/CHMP/SAWP/72894/2008-CONSULTATION, 24 April 2008).

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to David G Warnock or Carl C Peck.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Warnock, D., Peck, C. A roadmap for biomarker qualification. Nat Biotechnol 28, 444–445 (2010). https://doi.org/10.1038/nbt0510-444

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0510-444

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research